Arsanis, Inc. Human Resources Contracts & Agreements
45 Contracts & Agreements
- Bonus & Incentive Agreements (26 contracts)
- Compensation Agreements (1)
- Consulting Agreements (1)
- Employment Agreements (17)
- X4 Pharmaceuticals, Inc. Amended and Restated 2019 Inducement Equity Incentive Plan (Filed With SEC on August 10, 2023)
- X4 Pharmaceuticals, Inc. Amended and Restated 2019 Inducement Equity Incentive Plan (Filed With SEC on December 23, 2022)
- Form of Stock Appreciation Right Agreement under the X4 Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (Filed With SEC on November 9, 2022)
- Amended and Restated Executive Employment Agreement, dated as of March 7, 2022 by and between the Company and Mary DiBiase (Filed With SEC on March 17, 2022)
- Amended and Restated Executive Employment Agreement, dated as of March 7, 2022 by and between the Company and Diego Cadavid (Filed With SEC on March 17, 2022)
- Amended and Restated Executive Employment Agreement, dated as of March 7, 2022 by and between the Company and Art Taveres (Filed With SEC on March 17, 2022)
- Amended and Restated Executive Employment Agreement, dated as of March 7, 2022 by and between the Company and Derek Meisner (Filed With SEC on March 17, 2022)
- Second Amended and Restated Executive Employment Agreement, dated as of March 7, 2022 by and between the Company and Adam S. Mostafa (Filed With SEC on March 17, 2022)
- Executive Employment Agreement, dated as of November 23, 2020, by and between the Company and Diego Cadavid (Filed With SEC on March 19, 2021)
- Executive Employment Agreement, dated as of October 21, 2020, by and between the Company and Art Taveres (Filed With SEC on March 19, 2021)
- Consulting agreement, dated September 17 2020, by and between X4 Pharmaceuticals Inc. and Gary Bridger (Filed With SEC on November 5, 2020)
- Amendment to Amended and Restated Executive Employment Agreement, dated as of March 13, 2019, dated February 13, 2020 by and between the Company and Paula Ragan, Ph.D (Filed With SEC on May 7, 2020)
- Amendment to Executive Employment Agreement, dated as of February 24, 2020, by and between the Company and Derek Meisner (Filed With SEC on March 12, 2020)
- Executive Employment Agreement, dated as of September 25, 2019, by and between the Company and Derek Meisner (Filed With SEC on March 12, 2020)
- Amendment to Executive Employment Agreement, dated as of March 5, 2020, by and between the Company and E. Lynne Kelley (Filed With SEC on March 12, 2020)
- Amendment to Amended and Restated Executive Employment Agreement, dated as of February 24, 2020 by and between the Company and Adam S. Mostafa (Filed With SEC on March 12, 2020)
- Amendment to Amended and Restated Executive Employment Agreement, dated as of March 13, 2019, dated February 13, 2020 by and between the Company and Paula Ragan, Ph.D (Filed With SEC on March 12, 2020)
- Executive Employment Agreement, dated as of April 16, 2019, by and between the Company and E. Lynne Kelley (Filed With SEC on March 12, 2020)
- Form of Restricted Stock Unit Agreement under the Companys 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (Filed With SEC on June 19, 2019)
- Form of Restricted Stock Unit Agreement under the Companys 2017 Equity Incentive Plan (Filed With SEC on June 19, 2019)
- Form of Restricted Stock Unit Agreement under the 2019 Inducement Equity Incentive Plan (Filed With SEC on June 19, 2019)
- Form of Restricted Stock Agreement under the 2019 Inducement Equity Incentive Plan (Filed With SEC on June 19, 2019)
- Form of Stock Option Agreement under the 2019 Inducement Equity Incentive Plan (Filed With SEC on June 19, 2019)
- X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (Filed With SEC on June 19, 2019)
- Form of Incentive Stock Option Agreement under the 2017 Equity Incentive Plan (Filed With SEC on May 15, 2019)
- Form of Nonstatutory Stock Option Agreement under the 2017 Equity Incentive Plan (Filed With SEC on May 15, 2019)
- Form of Nonstatutory Stock Option Agreement (Director Grants) under the 2017 Equity Incentive Plan (Filed With SEC on May 15, 2019)
- Form of Restricted Stock Agreement under the 2017 Equity Incentive Plan (Filed With SEC on May 15, 2019)
- Form of Stock Option Agreement under the 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (Filed With SEC on April 3, 2019)
- Amended and Restated Executive Employment Agreement, dated as of March 13, 2019, by and between the Company and Adam S. Mostafa (Filed With SEC on March 13, 2019)
- Amended and Restated Executive Employment Agreement, dated as of March 13, 2019, by and between the Company and Paula Ragan, Ph.D (Filed With SEC on March 13, 2019)
- Director Compensation Policy (Filed With SEC on March 13, 2019)
- Form of Stock Option Agreement under the 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (Filed With SEC on March 13, 2019)
- 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (Filed With SEC on March 13, 2019)
- Form of Restricted Stock Agreement under the 2017 Equity Incentive Plan (Filed With SEC on November 27, 2018)
- Retention Bonus Agreement, dated November 26, 2018, by and between Arsanis, Inc. and Christopher Stevens (Filed With SEC on November 27, 2018)
- 2018 Amended and Restated Employment Agreement, dated November 26, 2018, by and between Arsanis, Inc. and Michael Gray (Filed With SEC on November 27, 2018)
- Form of Nonstatutory Stock Option Agreement under the 2017 Equity Incentive Plan (Filed With SEC on October 20, 2017)
- Form of Incentive Stock Option Agreement under the 2017 Equity Incentive Plan (Filed With SEC on October 20, 2017)
- 2017 Equity Incentive Plan (Filed With SEC on October 20, 2017)
